Author:
Manuel Gutiérrez-Gómez Víctor,Archundia-Jiménez Beatriz,Miguel González-Sánchez Rodrigo,Amado López-Arriaga Jerónimo,X. Pasco-Velázquez Beatriz,Gómez-Flores Alejandra
Abstract
Multisystem inflammatory syndrome was first detected in pediatric patients in April 2020, related to COVID-19. The clinical manifestations are very broad and overlap with Kawasaki disease. Various organizations have developed guides with case definitions in order to facilitate diagnosis and epidemiological reporting. In this chapter, we present the clinical manifestations of multisystem inflammatory syndrome, considering the case definition of various organizations and case series reports, systematic reviews, and meta-analyses. We also address multisystem inflammatory syndrome in adults in the neonatal period.
Reference19 articles.
1. Royal College of Paediatric and Child Health. Guidance: Pediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. 2020. Available from:
2. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Scientific Brief. 15 May 2020. WHO reference number: WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1. Available from:
3. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). 2020. Available from:
4. Melgar M, Lee EH, Miller AD, Lim S, Brown CM, Yousaf AR, et al. Council of State and Territorial Epidemiologists/CDC surveillance case definition for multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection – United States. MMWR. 2022;(4):1-14
5. Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: Optimizing definition and management. Pediatric Research. 2023;(6):1499-1508. DOI: 10.1038/s41390-022-02263-w